Abstract:Ovarian cancer usually responds well to chemotherapy, but once the disease becomes resistant to chemotherapy, the treatment options available are inadequate. A number of strategies are currently undergoing clinical evaluation, among which angiogenesis and PARP [poly(ADP-ribose) polymerase] inhibitors appear promising. Pre-clinical studies have identified several potential new therapeutic strategies, and we review the potential for use of BH3 (Bcl-2 homology) mimetics, autotaxin inhibitors and statins to treat … Show more
“…However, many patients experience recurrence and chemotherapy resistance, even though they response well initially. Consequently, the overall 5-year survival rate is about 40% after diagnosis with advanced-stage ovarian cancer [3]. Thus, effective and accessible adjuvant interventions for advanced-stage ovarian cancer are required.…”
Section: Introductionmentioning
confidence: 99%
“…On the other hand, emerging evidences supported the involvement of elevated cholesterol in reprogramming of metabolic program which augments the process of tumor development [6]. It has been suggested that statins inhibit cancer development through their inhibition of the mevalonate pathway, which could modify several proteins which is particularly necessary for the function of cancer cells, such as GTPases Ras, Rho, and Rab [3]. …”
Section: Introductionmentioning
confidence: 99%
“…However, the effect of statins in the clinical setting for the management of ovarian cancer patients remains unknown [3, 7]. Few studies reported the effect of statin therapy on ovarian cancer survival.…”
Section: Introductionmentioning
confidence: 99%
“…However, in a recent study that enrolled 442 ovarian cancer patients, improved survival among statin users was not demonstrated except in nonserous papillary epithelial ovarian cancer [10]. Furthermore, in some cancer cell lines, combining statin with carboplatin or paclitaxel revealed antagonistic effects, whereas the combination of taxane and platinum is a standard recommendation for ovarian cancer [3, 11]. …”
Background. Despite the great achievements in the treatment of advanced-stage ovarian cancer, it is still a severe condition with an unfavorable 5-year survival rate. Statins have been suggested to reduce the risk of several cancers beyond their cholesterol-lowing effects. However, the prognostic significance of statins in patients with advanced-stage ovarian cancer remains controversial. Methods. A retrospective study was performed to evaluate the association between statin intake and overall survival (OS) among patients with advanced-stage ovarian cancer. Patients who underwent cytoreductive surgery followed by courses of intravenous chemotherapy were matched through a propensity score analysis. Results. A total of 60 propensity-matched patients were included. Women in statin group showed a similar OS than the nonstatin counterparts (P = 0.966), whereas residual tumor was significantly associated with better OS (P = 0.013) and was an independent factor that associated with OS (P = 0.002, hazard ratio = 5.460, and 95% confidence interval: 1.894 to 15.742) in multivariable analysis. Conclusions. Our results suggested that statin usage was not associated with improved OS in patients with advanced-stage ovarian cancer undergoing surgery and chemotherapy. Considering the retrospective nature and the relative small sample size of the study, further prospective studies and random control trials are needed.
“…However, many patients experience recurrence and chemotherapy resistance, even though they response well initially. Consequently, the overall 5-year survival rate is about 40% after diagnosis with advanced-stage ovarian cancer [3]. Thus, effective and accessible adjuvant interventions for advanced-stage ovarian cancer are required.…”
Section: Introductionmentioning
confidence: 99%
“…On the other hand, emerging evidences supported the involvement of elevated cholesterol in reprogramming of metabolic program which augments the process of tumor development [6]. It has been suggested that statins inhibit cancer development through their inhibition of the mevalonate pathway, which could modify several proteins which is particularly necessary for the function of cancer cells, such as GTPases Ras, Rho, and Rab [3]. …”
Section: Introductionmentioning
confidence: 99%
“…However, the effect of statins in the clinical setting for the management of ovarian cancer patients remains unknown [3, 7]. Few studies reported the effect of statin therapy on ovarian cancer survival.…”
Section: Introductionmentioning
confidence: 99%
“…However, in a recent study that enrolled 442 ovarian cancer patients, improved survival among statin users was not demonstrated except in nonserous papillary epithelial ovarian cancer [10]. Furthermore, in some cancer cell lines, combining statin with carboplatin or paclitaxel revealed antagonistic effects, whereas the combination of taxane and platinum is a standard recommendation for ovarian cancer [3, 11]. …”
Background. Despite the great achievements in the treatment of advanced-stage ovarian cancer, it is still a severe condition with an unfavorable 5-year survival rate. Statins have been suggested to reduce the risk of several cancers beyond their cholesterol-lowing effects. However, the prognostic significance of statins in patients with advanced-stage ovarian cancer remains controversial. Methods. A retrospective study was performed to evaluate the association between statin intake and overall survival (OS) among patients with advanced-stage ovarian cancer. Patients who underwent cytoreductive surgery followed by courses of intravenous chemotherapy were matched through a propensity score analysis. Results. A total of 60 propensity-matched patients were included. Women in statin group showed a similar OS than the nonstatin counterparts (P = 0.966), whereas residual tumor was significantly associated with better OS (P = 0.013) and was an independent factor that associated with OS (P = 0.002, hazard ratio = 5.460, and 95% confidence interval: 1.894 to 15.742) in multivariable analysis. Conclusions. Our results suggested that statin usage was not associated with improved OS in patients with advanced-stage ovarian cancer undergoing surgery and chemotherapy. Considering the retrospective nature and the relative small sample size of the study, further prospective studies and random control trials are needed.
“…The activity of ABT-737 has previously been attributed to inhibition of the pro-apoptotic mediators, Bcl-2, Bcl-x L or Bcl-w, of which Bcl-x L is overexpressed in ovarian cancer (8,25). Statins have been shown to induce apoptosis through a number of pathways, including suppression of Akt/Erk activation (11,12), increased phosphorylation of the p38 MAPK pathway (12), and attenuation of Mcl-1, probably through the inhibition of NF-κB (26).…”
Abstract. There is considerable interest in redeploying drugs for use in combination with other oncology therapeutics. The single-agent activity of statins in ovarian cancer has been widely reported, however the drug concentration required to cause cell death is considerably higher than that achieved in patients receiving statin treatment for hypercholesterolemia. Unfortunately, statins can cause myopathy when administered in high doses. One solution to this is to identify drugs that could be used in combination with statins to reduce the dose required and those that may potentially reduce the incidence of adverse side effects. When the BH3 mimetic ABT-737, or the phosphatidylinositol 3-kinase inhibitor pictilisib, were combined with pitavastatin in cell growth assays using Ovcar-3 and Igrov-1 cells, the drug combinations were more effective than pitavastatin alone. In support of this, ABT-737 or pictilisib markedly increased cell death induced by pitavastatin in several ovarian cancer cell lines. The drugs were also synergistic in apoptosis assays. These observations suggested that either BH3 mimetics or pictilisib in combination with pitavastatin could be used in a subset of ovarian tumours, particularly those sensitive to BH3 mimetics, and phosphatase and tensin homolog inhibition, in the treatment of ovarian cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.